# Development of a Mitochondrial Permeability Transition‐Driven Necrosis‐Related Prognostic Signature in Cervical Cancer: Integrating Bulk Transcriptomic and Single‐Cell Data

**Authors:** Jiaojiao Niu, Sreenivasan Sasidharan

PMC · DOI: 10.1002/cam4.71094 · Cancer Medicine · 2025-08-01

## TL;DR

This study creates a new prognostic model for cervical cancer based on genes linked to mitochondrial cell death, showing potential for improved prediction and treatment.

## Contribution

A novel MPT-driven necrosis-related prognostic signature for cervical cancer using bulk and single-cell data.

## Key findings

- A risk signature based on ICOS, MMP3, and POSTN was developed and validated as an independent prognostic factor.
- MMP3 and POSTN knockdown reduced cervical cancer cell growth and migration in functional assays.
- The risk signature correlates with immune processes and cell communication involving endothelial and monocyte cells.

## Abstract

Cervical cancer (CC) is a prevalent gynecological malignancy with notable heterogeneity. The role of mitochondrial permeability transition (MPT)‐driven necrosis, a form of cell death due to mitochondrial dysfunction, in CC progression and prognosis is poorly understood and represents a promising therapeutic target for cancers. This study aimed to create a new prognostic signature linked to MPT‐driven necrosis, improving CC prediction and prognosis.

This study utilized the GSE63514, TCGA‐CESC, CGCI‐HTMCP‐CC, and GSE197641 transcriptome datasets. Firstly, the GSE63514 dataset was utilized to identify differentially expressed genes (DEGs). Differentially expressed MPT‐driven necrosis‐related genes (DE‐MRGs) were obtained by intersecting DEGs with MRGs. Regression analyses were performed to identify genes significantly associated with prognosis. A prognostic model was established in TCGA‐CESC, followed by independent validation and nomogram construction. Additional analyses included immune infiltration, enrichment analysis, and drug susceptibility based on high‐ and low‐risk groups. Finally, cell communication analysis was performed to investigate interactions between key cell types.

A total of 156 DE‐MRGs were identified. Regression analyses identified three prognostic genes (ICOS, MMP3, and POSTN) to construct a prognostic risk signature. Then, risk score was an independent prognostic factor for CC, and a nomogram demonstrated effective predictive accuracy for CC survival outcomes. The risk signature was linked to immune‐associated processes such “Antigen processing and presentation” and immune cell infiltration, especially M0 macrophages and CD8 T cells. Cell communication analysis uncovered a strong interaction between endothelial cells and monocytes. To validate the molecular mechanisms, qRT‐PCR, cell proliferation, and wound healing assays were performed. Functional tests showed that MMP3 and POSTN knockdown drastically reduced CC cell growth and migration.

This study developed a novel prognostic risk signature based on ICOS, MMP3, and POSTN. MMP3 and POSTN knockdown significantly decrease CC cell growth and migration, highlighting their potential as therapeutic targets.

## Linked entities

- **Genes:** ICOS (inducible T cell costimulator) [NCBI Gene 29851], MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314], POSTN (periostin) [NCBI Gene 10631]
- **Diseases:** cervical cancer (MONDO:0002974)

## Full-text entities

- **Genes:** GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, ICOS (inducible T cell costimulator) [NCBI Gene 29851] {aka AILIM, CD278, CVID1}, ZP4 (zona pellucida glycoprotein 4) [NCBI Gene 57829] {aka ZBP, ZP1, ZP1B, ZPB, ZPB2, Zp-4}, NLRC3 (NLR family CARD domain containing 3) [NCBI Gene 197358] {aka CLR16.2, NOD3}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, RHOH (ras homolog family member H) [NCBI Gene 399] {aka ARHH, IMD129, TTF}, LOC102723996 (ICOS ligand) [NCBI Gene 102723996], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, GSDMB (gasdermin B) [NCBI Gene 55876] {aka GSDMB-1, GSDML, PP4052, PRO2521}, PYHIN1 (pyrin and HIN domain family member 1) [NCBI Gene 149628] {aka IFIX}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GPR171 (G protein-coupled receptor 171) [NCBI Gene 29909] {aka H963}, PPIF (peptidylprolyl isomerase F) [NCBI Gene 10105] {aka CYP3, CyP-M, Cyp-D, CypD}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TRAT1 (T cell receptor associated transmembrane adaptor 1) [NCBI Gene 50852] {aka HSPC062, TCRIM, TRIM, pp29/30}, IL12RB1 (interleukin 12 receptor subunit beta 1) [NCBI Gene 3594] {aka CD212, IL-12R-BETA1, IL12RB, IMD30}, ITGAV (integrin subunit alpha V) [NCBI Gene 3685] {aka CD51, IDNDC, MSK8, VNRA, VTNR}, IL18BP (interleukin 18 binding protein) [NCBI Gene 10068] {aka FVH, IL18BPa}, ZBP1 (Z-DNA binding protein 1) [NCBI Gene 81030] {aka C20orf183, DAI, DLM-1, DLM1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PIK3R5 (phosphoinositide-3-kinase regulatory subunit 5) [NCBI Gene 23533] {aka F730038I15Rik, FOAP-2, P101-PI3K, p101}, NUCLEOLIN (nucleolin multifunctional protein) [NCBI Gene 4691] {aka C23, NCL, Nsr1}, RBP4 (retinol binding protein 4) [NCBI Gene 5950] {aka MCOPCB10, RDCCAS}, RREB1 (ras responsive element binding protein 1) [NCBI Gene 6239] {aka FINB, HNT, LZ321, RREB-1, Zep-1}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, LGALS9 (galectin 9) [NCBI Gene 3965] {aka HUAT, LGALS9A}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, CYTIP (cytohesin 1 interacting protein) [NCBI Gene 9595] {aka B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SLC25A4 (solute carrier family 25 member 4) [NCBI Gene 291] {aka AAC1, ANT, ANT 1, ANT1, MTDPS12, MTDPS12A}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, CD3G (CD3 gamma subunit of T-cell receptor complex) [NCBI Gene 917] {aka CD3-GAMMA, CD3GAMMA, IMD17, T3G}, ICOSLG (inducible T cell costimulator ligand) [NCBI Gene 23308] {aka B7-H2, B7H2, B7RP-1, B7RP1, B7h, CD275}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, SH2D1A (SH2 domain containing 1A) [NCBI Gene 4068] {aka DSHP, EBVS, IMD5, LYP, MTCP1, SAP}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, CYBB (cytochrome b-245 beta chain) [NCBI Gene 1536] {aka AMCBX2, CGD, CGDX, GP91-1, GP91-PHOX, GP91PHOX}
- **Diseases:** hypoxic (MESH:D002534), CC (MESH:D002583), precancerous (MESH:D011230), cervical squamous cell carcinoma (MESH:D002294), renal cell carcinoma (MESH:D002292), MPT (MESH:D008579), mitochondrial (MESH:D028361), T cell dysfunction (MESH:C536780), lung adenocarcinoma (MESH:D000077192), cholangiocellular carcinoma (MESH:D018281), colon cancer (MESH:D015179), breast cancer (MESH:D001943), carcinogenesis (MESH:D063646), uterine corpus endometrial carcinoma (MESH:D016889), IMM (MESH:D015433), gynecological malignancy (MESH:D005833), glioma (MESH:D005910), Necrosis (MESH:D009336), metastasis (MESH:D009362), RCD (MESH:D003643), melanoma (MESH:D008545), hepatocellular carcinoma (MESH:D006528), infection (MESH:D007239), inflammation (MESH:D007249), Malignant Tumors (MESH:D009369), cervical adenocarcinoma (MESH:D000230), prostate cancer (MESH:D011471), cardiac and degenerative diseases (MESH:D006331), laryngeal squamous cell carcinoma (MESH:D000077195), Tumor immune dysfunction (MESH:D007154)
- **Chemicals:** Dasatinib (MESH:D000069439), RDEA119 (MESH:C544830), TRIzol (MESH:C411644), Bortezomib (MESH:D000069286), BMS.708163 (MESH:C554092), Bleomycin (MESH:D001761), BMS.509744 (-), CI.1040 (MESH:C120227), Camptothecin (MESH:D002166), mitomycin C (MESH:D016685), ATP (MESH:D000255), Shikonin (MESH:C016101), Rapamycin (MESH:D020123), Gemcitabine (MESH:D000093542), cisplatin (MESH:D002945), BMS.536924 (MESH:C504983), paclitaxel (MESH:D017239), ROS (MESH:D017382), LPS (MESH:D008070), Lapatinib (MESH:D000077341), CO2 (MESH:D002245), Pazopanib (MESH:C516667), temsirolimus (MESH:C401859), Cyclopamine (MESH:C000541), PBS (MESH:D007854), Obatoclax (MESH:C520962)
- **Species:** Human papillomavirus (species) [taxon 10566], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** ECt1/ — Homo sapiens (Human), Transformed cell line (CVCL_3679), CC — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_JX14), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), SiHa — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_0032), CaSki — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_1100), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), E6E7 — Homo sapiens (Human), Transformed cell line (CVCL_UZ61), DLD-1 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0248)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12314548/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12314548/full.md

## References

97 references — full list in the complete paper: https://tomesphere.com/paper/PMC12314548/full.md

---
Source: https://tomesphere.com/paper/PMC12314548